Press Release · Florida Cancer Specialists & Research Institute
Florida Cancer Specialists & Research Institute Wins Global Gold MarCom Award for 2025 Year in Review Report
Distributed by BlessFeed · Originally issued via PR Newswire
FORT MYERS, Fla., Nov. 4, 2026 — Florida Cancer Specialists & Research Institute, LLC (FCS) has been recognized as a Gold Award Winner by the MarCom Awards for the content and design of its 2025 Year in Review. This marks the fourth consecutive year that the FCS annual report has received top industry honors for communications excellence.
"This recognition reflects the collaboration, creativity and dedication of an exceptional team," said Michelle Robey, FCS senior vice president of marketing & communications. "I am grateful for each team member who so skillfully captured our strategic priorities and the meaningful impact of our work."
The FCS 2025 Year in Review captures a year of growth, innovation and impact, showcasing expanded access to innovative treatments, advances in precision medicine and research, and creating better outcomes for cancer patients across Florida and beyond.
FCS CEO Ryan Ciarrocchi said, "At FCS, we are improving lives every day and helping shape the future of cancer care. This report highlights the dedication of our physicians, advanced practice providers and team members, whose unwavering commitment to excellence continues to elevate the patient experience and positively impact the communities we serve."
Administered by the Association of Marketing & Communications Professionals and recognized as one of the world's largest competitions honoring excellence in marketing and communications, the MarCom Awards receives approximately 6,000 print and digital entries annually from across the globe.
View the full list of winners: MarCom Gold Award Winners
SOURCE Florida Cancer Specialists & Research Institute
About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)
For more than 40 years, Florida Cancer Specialists & Research Institute (FCS) has embraced innovation to deliver world-class care and drive the dramatic transformation of oncology care through its robust clinical research program.
FCS provides patients with access to a wide range of clinical trials, positioning it as a leader in research among private oncology practices in Florida and across the country. Through its robust clinical research program with Sarah Cannon Research Institute (SCRI) and a suite of independent site management programs, with advanced clinical trial matching technology, FCS offers patients innovative therapies close to home. Each year, FCS conducts more than 180 active clinical trials that directly elevate patient care and accelerate progress in oncology. Many of the cancer drugs approved by the FDA in the U.S over the past decade were accessible to patients at FCS through clinical trial participation before receiving approval.
Our outstanding team of highly trained and dedicated physicians is committed to delivering tailored treatment plans that make the best use of cutting-edge precision oncology advancements to enhance patient outcomes.